DeepValue Capital’s bullish thesis on CONMED Corporation highlights strong fundamentals and growth potential. Despite a 70% drop from 2021 highs, revenue is up 30% and free cash flow up 50%. With industry tailwinds and margin expansion, the company could more than double in value over the next three years.

Conmed Corporation is a global medical device company founded in 1970, specializing in less invasive surgery. With key acquisitions and high-margin products, the company generated $1.3 billion in revenue in 2024. Around 45% of sales come from international markets, with a focus on orthopedic and general surgery products.

Stryker Corporation, a competitor of Conmed, has seen a 2.22% stock price increase since coverage by The Antifragile Investor. Both companies emphasize innovation and growth, with Conmed’s supply chain recovery, high-margin products, and strong free cash flow standing out as investment opportunities.

Read more at Yahoo Finance: CONMED Corporation (CNMD): A Bull Case Theory